Inclusion Criteria:

- Histologically confirmed malignancy

- Metastatic or unresectable

- No standard curative or palliative measures exist or are ineffective

- Brain metastases allowed provided 1 of the following criteria is met:

- Lesions were previously treated with surgery, radiotherapy, or chemotherapy AND
are currently asymptomatic AND no steroid therapy or antiseizure medication
within the past 2 weeks

- Untreated, asymptomatic metastases AND no requirement for steroid therapy or
antiseizure medication

- Performance status - ECOG 0-2

- More than 12 weeks

- WBC at least 3,000/mm^3

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Bilirubin normal

- SGOT/SGPT no greater than 2.5 times upper limit of normal

- Albumin at least 3.0 mg/dL

- Creatinine normal

- Creatinine clearance at least 60 mL/min

- No symptomatic congestive heart failure, unstable angina pectoris, or cardiac
arrhythmia

- No prior allergic reactions to compounds of similar chemical or biologic composition
to benzoylphenylurea

- No neuropathy greater than grade 1

- No other uncontrolled medical or psychiatric illness that would preclude study
compliance

- No ongoing or active infection

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Prior immunotherapy allowed

- No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)
and recovered

- At least 2 weeks since steroids for CNS disease

- At least 4 weeks since prior radiotherapy and recovered

- Prior surgery allowed

- At least 2 weeks since antiseizure medications for CNS disease

- More than 7 days since prior CYP3A4 or CYP2D6 inhibitors

- More than 7 days since prior CYP3A4 inducers

- No concurrent CYP3A4 or CYP2D6 inhibitors

- No concurrent CYP3A4 inducers

- No other concurrent investigational agents

- No concurrent combination anti-retroviral therapy for HIV